Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels

Harvala, Heli, Robb, Matthew L., Watkins, Nick, Ijaz, Samreen, Dicks, Steven, Patel, Monika, Supasa, Piyada, Wanwisa, Dejnirattisai, Liu, Chang, Mongkolsapaya, Juthathip, and others. (2020) Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfusion Medicine, . ISSN 0958-7578. E-ISSN 1365-3148. (doi:10.1111/tme.12746) (KAR id:84860)

PDF Publisher pdf Language: English
Download this file (PDF/2MB)
Request a format suitable for use with assistive technology e.g. a screenreader
Official URL: https://dx.doi.org/10.1111/tme.12746

Abstract

Introduction

The lack of approved specific therapeutic agents to treat coronavirus disease (COVID‐19) associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has led to the rapid implementation of convalescent plasma therapy (CPT) trials in many countries, including the United Kingdom. Effective CPT is likely to require high titres of neutralising antibody (nAb) in convalescent donations. Understanding the relationship between functional neutralising antibodies and antibody levels to specific SARS‐CoV‐2 proteins in scalable assays will be crucial for the success of a large‐scale collection. We assessed whether neutralising antibody titres correlated with reactivity in a range of enzyme‐linked immunosorbent assays (ELISA) targeting the spike (S) protein, the main target for human immune response.

Methods

Blood samples were collected from 52 individuals with a previous laboratory‐confirmed SARS‐CoV‐2 infection. These were assayed for SARS‐CoV‐2 nAbs by microneutralisation and pseudo‐type assays and for antibodies by four different ELISAs. Receiver operating characteristic (ROC) analysis was used to further identify sensitivity and specificity of selected assays to identify samples containing high nAb levels.

Results

All samples contained SARS‐CoV‐2 antibodies, whereas neutralising antibody titres of greater than 1:20 were detected in 43 samples (83% of those tested) and >1:100 in 22 samples (42%). The best correlations were observed with EUROimmun immunoglobulin G (IgG) reactivity (Spearman Rho correlation coefficient 0.88; p < 0.001). Based on ROC analysis, EUROimmun would detect 60% of samples with titres of >1:100 with 100% specificity using a reactivity index of 9.1 (13/22).

Discussion

Robust associations between nAb titres and reactivity in several ELISA‐based antibody tests demonstrate their possible utility for scaled‐up production of convalescent plasma containing potentially therapeutic levels of anti‐SARS‐CoV‐2 nAbs.

Item Type:	Article
DOI/Identification number:	10.1111/tme.12746
Uncontrolled keywords:	convalescent plasma, COVID‐19, neutralising antibody level, SARS‐CoV‐2 testing of plasma
Subjects:	Q Science > QR Microbiology > QR355 Virology
Divisions:	Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User:	Nigel Temperton
Date Deposited:	20 Dec 2020 00:07 UTC
Last Modified:	05 Nov 2024 12:51 UTC
Resource URI:	https://kar.kent.ac.uk/id/eprint/84860 (The current URI for this page, for reference purposes)

University of Kent Author Information

Temperton, Nigel.

Creator's ORCID:	https://orcid.org/0000-0002-7978-3815
CReDIT Contributor Roles:

Depositors only (login required):

Altmetric

Download Statistics

Total unique views for this document in KAR since July 2020. For more details click on the image.